In 2004, we pledged a grant of £1 million to the Institute of Cancer Research. Over the next ten years, this grant would fund pioneering research into prostate cancer.
We are pleased to announce that this research has yielded some very exciting results– identifying 80 molecular weaknesses in prostate cancer that could be targeted by drugs.
Study co-author Professor Paul Workman, Chief Executive of the ICR, said:
This study has uncovered a remarkably large number of new genes that drive the development of prostate cancer, and given us vital information about how to exploit the biology of the disease to find potential new treatments.
New approaches to treatment
The study – which is the largest and most comprehensive ever conducted into the genes that drive prostate cancer – found that around a quarter of these mutations involve the targets of existing drugs that are either licensed or in clinical trials. This suggests that these could offer promise for further study as new approaches to treatment. Additionally, 60 new potential targets for prostate cancer treatment were identified for future investigation, as well as identifying many new genes associated with the development of the disease.